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ABSTRACT
LUNASIN REDUCES THE MELANOMA STEM CELL POPULATION IN
VITRO AND INHIBITS TUMOR PROLIFERATION IN VIVO
Christopher P. Shidal
October 30, 2014
Lunasin is a 44 amino acid peptide derived from the soybean seed that has been shown to
have cancer chemopreventive and chemotherapeutic properties. In this study, we
investigated the potential utility of lunasin as a chemotherapeutic in a melanoma model.
Initial studies showed that lunasin has little activity against established melanoma cell
lines in vitro using adherent culture methods; however, lunasin’s in vitro activity was
significantly higher in non-adherent colony-forming assays in soft agar and oncosphere
assays. These results led us to investigate whether lunasin selectively affects cancer
initiating cells (CIC) that are known to be present in these melanoma cell lines. We found
that lunasin treatment did selectively inhibit the proliferation of high-ALDH-expressing
malignant melanoma initiating cells (MMIC) in vitro, and had the striking effect of
preventing oncosphere formation under non-adherent culture conditions. These in vitro
results were extended into mouse xenograft studies using both bulk melanoma cells and
isolated CICs. Lunasin significantly inhibited tumor growth in both cases, with the
highest inhibition being observed in tumors initiated by MMICs. Mechanistic studies
suggested that lunasin inhibits CIC proliferation in vitro through interactions with
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integrins and disruption of integrin signaling by inhibiting the activity of integrin binding
partners such as integrin-linked kinase (ILK) and focal adhesion kinase (FAK). These
studies demonstrate for the first time that lunasin has activity against putative CICs and
that lunasin may have utility as a therapeutic agent for the treatment of melanoma.
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INTRODUCTION
Lunasin as an Anticancer Agent
Lunasin is a soy derived peptide that has demonstrated anticancer, antiinflammatory, antioxidant, and immunomodulatory activity [1-4]. Lunasin has been
reported as a 43 amino acid fragment present in processed 2S albumin protein [5];
however, we recently identified a native 44 amino acid sequence of lunasin isolated from
defatted soy flour consisting of the sequence:
SKWQHQQDSCRKQLQGVNLTPCEKHIMEKIQGRGDDDDDDDDDN [6]. Lunasin
has been proposed to have three distinct domains that are responsible for its therapeutic
and chemopreventive activity: an RGD sequence involved in internalization of the
peptide via integrin binding, a poly-aspartic acid tail that binds lysine residues present in
H3 and H4 histone tails, and a hypothesized chromatin binding domain [7, 8]. Limited
studies describe the direct chemotherapeutic effects of lunasin against cancer as it is
generally defined as a chemopreventive agent based on earlier studies by de Lumen and
coworkers [7, 9-12]. Thus, many questions remain about the number of cancer types
sensitive to lunasin, the possible mechanisms of lunasin’s anticancer effects, and to what
extent lunasin is involved with the tight correlation of soy consumption with a protective
effect against certain cancer types [13-15].
Lunasin has been found to inhibit transformation induced by multiple carcinogens
and viral oncogenes [7, 9, 16-18]. Moreover, studies in our lab indicate lunasin is able to
inhibit transformation of mouse fibroblast cells induced by carcinogens present in
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cigarette smoke including cadmium and nicotine-derived nitrosamine ketones (data not
shown). The most discussed mechanism of action of lunasin is the inhibition of histone
acetyltransferases (HATs) and modulation of histone acetylation.
The acetylation of core histones initiates the unwinding of tightly packed DNA
from the nucleasome complex allowing for transcription of target genes (Figure 1). HAT
inhibition alters normal acetylation patterns leading to hypoacetylation of histone tails,
repressing transcription and can account for global cellular effects including proliferation,
cell cycling, and apoptosis [19-21].

Although some evidence supports HAT inhibition

as lunasin’s primary mechanism of action, to date, there have been no functional studies
to support this hypothesis. Moreover, as new principal mechanisms of lunasin action are
still being discovered, it is not clear in the different experimental systems that have been
studied whether histone acetylation is involved in all cases.
Studies in our lab confirm a significant antiproliferative effect of lunasin on nonsmall cell lung cancer (NSCLC), an effect which is mediated by disrupting cell cycle
signaling (McConnell, 2014). Previous studies have acknowledged that lunasin reduces
cyclin-dependent kinase (CDK) levels, and may accommodate aspirin-induced apoptosis
in breast cancer models [22, 23]. Additionally, lunasin was reported to induce apoptosis
and alter expression of matrix adhesion proteins in metastatic colon cancer [24]. Lunasin
was recently shown to suppress FAK/ERK/NF-κB signaling in human colon cancer as
well as potentiate the antiproliferative and antimetastatic effects of oxaliplatin [25].
Sadly, many plant-derived compounds (e.g. curcumin) are quickly metabolized
or excreted resulting in poor bioavailability, however, lunasin is active and bioavailable
in humans consuming physiologically relevant amounts of soy [26]. In this study,
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volunteers were orally dosed with lunasin (155.5 mg/day) in 50 grams (g) soy protein for
5 consecutive days. De Mejia et al. revealed lunasin is orally bioavailable; however,
incomplete GI absorption resulted in a low concentration (71.0 ng/mL or
approximately14 μM) lunasin in plasma samples [26].
Prior studies suggest that lunasin interacts with a specific subset of integrin
subunits, as supported by a 2012 study by De Meija and coworkers [2]. Furthermore,
recent studies suggest that internalization of lunasin is mediated by αvβ3 integrins via
clathrin and caveolin-mediated endocytosis [27]. Proximity ligation assays (PLA) verify
that the specific integrin subunits αv, α5, β1 and β3 network with the lunasin peptide
(Inaba and Davis, unpublished data). In normal cells, integrins mediate cell-cell and cellmatrix adhesions by recognizing binding motifs (i.e. RGD) as well as cooperating with
growth factor receptors to induce proliferative and survival signaling [28, 29]. The
ubiquitous nature of integrin signaling provides an interesting target for cancer
prevention and treatment because many of these pathways are deregulated in cancer and
result in uncontrolled proliferation and metastasis. More specifically, we are interested in
elucidating the effects of lunasin treatment on downstream pathways associated with
integrin signaling and how disrupting these pathways can therapeutically benefit
melanoma patients.
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Integrins as a targeted therapy in melanoma patients
Integrins are vital to most cellular processes, and remain an important and
underexplored target for cancer therapies. Recent studies utilizing RGD peptides have
shown targeting of integrins as a viable treatment alternative in melanoma therapy by
inhibiting tumor angiogenesis, growth, and metastasis [30-32]. Integrins are
heterodimeric membrane proteins primarily implicated in cell adhesion and migration
[33, 34]; yet, integrins have also been reported to be intimately involved in cell growth,
differentiation, and survival [35, 36]. Two families consisting of 18 α-subunits and 8 βsubunits comprise the 24 heterodimeric proteins known in humans [37], combined with
complex conformational states and overlapping ligand specificities, make integrin
signaling flexible yet highly intricate [38]. Furthermore, integrin expression profiles are
largely dependent upon two dimensional (i.e. adherent conditions) adhesion versus three
dimensional (i.e. non-adherent) adhesion [39], and can result in recruitment of very
different subsets of proteins. Proteins attracted to different adhesion structures (e.g.
paxillin) can produce diverse yet specific signaling cascades.
By categorizing NSCLC lines based on integrin expression profiles, we associated
explicit integrin subunits with lunasin sensitivity (McConnell and Davis, unpublished
data). Moreover, we showed lunasin exerts its anticancer effects in NSCLC by reducing
activating phosphorylations of v-akt murine thymoma viral oncogene homolog 1 (AKT),
Focal adhesion kinase (FAK), and interactions of β-subunits with integrin-linked kinase
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(ILK), thereby altering signaling pathways downstream of integrin-ligand binding
(unpublished data).
In melanoma models, the integrin αvβ3 is currently the predominant target for
therapeutic applications of integrin antagonists. Integrin αvβ3 is expressed at low levels
in non-transformed epithelial cells relative to melanoma cells [40], as αvβ3 expression
has been related to metastatic potential and dissemination of melanoma neoplasms to a
metastatic phenotype [41, 42]. Crosstalk between integrins and growth factor receptors
has been well documented [43, 44]. Enhanced cancer cell survival has been attributed to
a number of interactions between integrin signaling and other pathways including
increased BCL-2 expression, PI3K-AKT activation, or NF-κB signaling [45-47]. We
predict that lunasin binds αvβ3 integrins through its RGD domain and inhibits
proproliferative and prosurvival signaling.
Certain integrins have specific roles in melanoma; for instance, it has been shown
that α4β1, a homing molecule on leukocytes that binds VCAM-1, is absent on
melanoctyes, yet present in melanoma cultures [48]. Consequently, α4β1 may help
melanomas mimic hematopoietic cells by enabling melanoma migration into tissues that
express sing VCAM-1 [49]. Other integrins implicated in melanoma are α3β1 and α5β1,
which were elevated in metastatic melanoma tissue. Furthermore, α1β1, α2β1 and α6β1
integrin subunits were found to be reduced in metastatic versus primary melanoma [48].
Roles of integrins in CICs are somewhat ambiguous. Recent studies show that
integrin subunits may be a viable marker for CICs and are responsible for stem cell pool
maintenance and differentiation mediated by FAK [50, 51]. CICs are proposed to be
more tumorigenic based on properties such as chemoresistance, immune evasion, and
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self-renewal capabilities [52, 53]. Cilengitide (Merck Co.), a cyclic RGD (cRGD)
peptide, has been used to treat glioblastoma and is the first integrin inhibitor to be used in
Phase III clinical trials [54]. By selectively targeting melanoma stem cells and altering
integrin signaling, we may provide a novel treatment for malignant metastatic melanoma.
Furthermore, targeting of integrin subunits explicitly expressed on cancer cells may
represent a dynamic solution to reducing off-site, adverse side effects generally seen with
traditional chemotherapy.
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Melanoma and the presence of melanoma stem cells
Skin cancers account for nearly half of all diagnosed cancer cases in the United
States and have increased in frequency over the last thirty years [55]. Melanoma is
estimated to account for 76,000 new cancer cases in 2014 [56]. Despite being less
frequent than other skin cancers, nearly 75% of skin cancer deaths are attributed to
melanoma [56]. Even more unnerving, NCI’s Surveillance, Epidemiology, and End
Results (SEER) program estimates cases of melanoma have nearly tripled in the past
thirty years increasing from 7.9 (per 100,000) in 1975 to 22.7 in 2011, while 5-year
survival rates remain constant. Early detection and diagnosis is paramount for overall
survival with 5-year survival rates of 98%, 62%, and 16% for localized, regional, and
distant diseases, respectively [56]. Continued research of melanoma has provided several
“cracks in the armor” of metastatic melanoma leading to the development of several
targeted therapies that aim to inhibit proliferation, metastasis, and angiogenesis of
primary and secondary tumors. One such targeted therapy is vemurafenib, which
decreases melanoma cell viability and proliferation resulting in tumor regression and
increasing overall mean survival time [57, 58].
Vemurafenib targets a mutated form of the B-Raf protein found in approximately
60% of melanomas in which a V600E substitution leads to constitutive Raf signaling
within the mitogen-activated protein kinase (MAPK) cascade [59]. In the majority of
patients harboring this mutation, mean survival time has been improved with
vemurafenib; however, after initial tumor regression, many patients experience
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recurrence of tumors that are vemurafenib-resistant [60-62]. Conferred resistance to
vemurafenib may occur through a number of mechanisms including, but not limited to,
feedback activation of epithelial growth factor receptor (EGFR), upregulation of other
Raf proteins, or upregulation of N-Ras [62-64]. Our present studies focus on developing
lunasin as an adjuvant therapy to targeted therapies such as vemurafenib. We found that
lunasin interacts additively with vemurafenib to reduce the ability of melanoma cells to
proliferate and form oncospheres in vitro, and may sensitize cell lines with acquired
resistance to subsequent vemurafenib treatments via inhibition of PI3K/AKT signaling
(data not shown).
One explanation for the reformation of palpable tumors with chemoresistance is
the presence of CICs within the bulk tumor population. The presence of CICs and their
origin have become a topic of debate [65-69]. According to the cancer stem cell (CSC)
theory, a subset of cells within the tumor population have properties that resemble
physiological stem cells including the ability to self-renew while also giving rise to
daughter cells that differentiate to reform heterogeneous tumor populations [65]. In this
study, we will show that CICs exist within bulk tumor populations at a relatively high
rate, and that this subset of cells displays enhanced tumorigenicity.
Discovery of melanoma cells with stem-like plasticity was initially found in
patient tumors overexpressing CD20 and CD133 [70, 71]. CD20 is a membranespanning surface molecule generally found on B lymphocytes; per se, it is the molecular
target for monoclonal antibodies (e.g. rituximab) for treatment of select leukemias and
lymphomas. CD133 (also called prominin-1) is a novel, membrane-spanning protein of
no known function that is classified as a marker for primitive hematopoietic and neural
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stem cells. These subsets of cells were found to have properties of stem cells as well as
enhanced ability to form palpable tumors in immunodeficient mice. Ensuing studies
verify ATP-binding cassette sub-family B member 5 (ABCB5), a drug transporter
playing a key role in chemoresistance, and Low-Affinity Nerve Growth Factor Receptor
(LNGFR/CD271), a member of the tumor necrosis factor (TNF) receptor family
involved in survival and differentiation of neurons, as viable MMIC biomarkers [53, 72].
However, scientists are slow to embrace this concept for a number of valid reasons. One
concern remains the standardization of techniques for identifying and propagating cancer
stem cells. Serial dilution and transplantation of CICs into NOD/SCID mice has long
been the gold standard for determining stem cell populations; however, spheroid assays
in addition to genetic lineage tracing provide in vitro assays for CIC classification [66].
To make matters more complicated, some evidence supports plasticity of
differentiated cancer cells in a breast cancer model [73]. By reverting to a
dedifferentiated phenotype, stem-like cells arise de novo in response to environmental
cues [73]. These data support the theory of bidirectional movement between stem and
non-stem compartments, and have serious implications on the plasticity of cells in cancer
models as well as subsequent therapeutic strategies.
Although populations of stem-like cells are recognized in melanoma cell lines, the
frequency of these cells is highly variable, ranging from less than 1% up to nearly 25%
[53, 74]. The incidence of cancer stem cells seems dependent upon the in vivo model, the
biomarker used for identification, and the tumor microenvironment [49, 75]. Conflicting
reports indicate that tumor samples enriched for MMIC markers have enhanced tumor
forming capacity. Quintana [74] showed tumorigenic cells are phenotypically
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heterogeneous in melanomas, as significant in vivo tumor growth was marginal based on
select CSC biomarkers. Despite these findings, numerous studies report superior tumor
forming capabilities of cells enriched for melanoma stem cell biomarkers including
ABCB5 [76], CD133 [71], CD271 [72], and ALDH [77].
Aldehyde dehydrogenase (ALDH) is a family of detoxifying enzymes responsible
for metabolism of certain alkylating agents such as cyclophosphamide. Enrichment for
melanoma intiating cells by intracellular ALDH staining has come with mixed reviews;
however, most evidence supports ALDH as a MMIC biomarker [77-80]. ALDH
expression has also successfully been used to detect CICs in breast and colon cancer
models [81, 82]. In this study, we implement a commercially available ALDH detection
kit to identify and sort melanoma cells expressing elevated levels of ALDH from ALDH
negative fractions.
Unfortunately, current therapeutics heavily rely on efficacy against bulk tumor
cells and the ability of the drug to reduce primary or secondary tumor size. We suggest
that lunasin specifically targets MMICs and reduces this aggressive subpopulation of
cells. We are currently elucidating mechanisms for this effect, but believe lunasin
treatment may induce terminal differentiation of cancer stem cells, inhibit self-renewal
capacity, or alter integrin signaling leading to antiproliferative effects. By reducing CIC
populations, we hypothesize lunasin alters the ability of melanoma tumor cells to
establish palpable tumors in vivo. By selectively reducing the population of melanoma
cells with the ability to form solid tumors and metastasize, lunasin has a potential
therapeutic application.
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METHODS
Lunasin Isolation and Purification
Lunasin was isolated from “white flake,” a product resulting from the flaking and
defatting of soybeans via hexane extraction. The extraction and purification was scaled
and performed by Kentucky BioProcessing (KBP) as previously described [6]. Briefly,
lunasin was extracted from defatted soy flour and purified using a combination of QSepharose FF chromatography, ultrafiltration utilizing a 30 kDa membrane, and. reversephase chromatography. Sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) analysis indicate these lunasin preparations have >99% purity.
Cell Culture and Reagents
SKMEL-28 and A375 cell lines were obtained from American Type Culture
Collection (ATCC, Rockville, MD, USA). Cell lines were grown in Dulbeccos Modified
Eagles Medium (DMEM) and supplemented with 10% fetal bovine serum (FBS), 100
U/mL penicillin, and 100 μg/mL streptomycin. Cells were incubated at 37˚C at 5% CO2
and subcultivated every 72 hours. Vemurafenib was obtained from Selleck Chemicals
(Houston, TX). DMEM media (Invitrogen) was reconstituted in 500mL ultrapure H2O
and supplemented with 20% FBS, 200 U/mL penicillin, and 200 μg/mL streptomycin for
use in soft agar assays.
Proliferation Assays
Manufacturer protocols were followed to determine effect of lunasin on
melanoma cell proliferation (Promega Cell titer-96 Aqueous Reagent). Initial seeding
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densities were standardized at 7.5x 103 cells/cm2 in 100 μL culture media. Briefly, cells
were plated and incubated at 37˚C, 5% CO2 for 4 hours. Media were drained from each
well and replaced with media containing varying concentrations of lunasin. Treatment
media were replaced every 24 hours during the 72 hour treatment period. After 72 hours
of treatment, wells were drained of expired media and refilled with fresh media. 20 μL
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium (MTS) reagent was added to each well and the plate was incubated for 2-3
hours. Absorbance was read at 490 nm on a plate reader (Biotek Instruments, Winooski,
VT). Average absorbance of media containing no cells was subtracted from all
absorbance values. Absorbance values were then normalized to control and expressed as
percent control.
Soft Agar Colony Forming Assay
In order to assess the ability of lunasin to suppress anchorage-independent growth
of cancer cell lines, cells were suspended in soft agar. Solutions of 1% and 0.7% w/v
Bacto Agar were mixed with equal volumes (1:1) of 2x DMEM media containing 20%
FBS and 2% Pen-Strep. 2 mL of 0.5% agar solution was used to coat the bottom of each
well in a 6-well plate and allowed to solidify in a laminar flow hood. 1x 103 cells were
suspended in a 1 mL top layer containing 0.3% agar with and without lunasin present and
placed on top of the bottom layer of agar. Plates were allowed to fully solidify and were
placed in the incubator. Generally, colony formation occurred within 2-3 weeks.
Colonies were stained with a 1 mg/mL iodonitrotetrazolium chloride (Sigma-Aldrich, St.
Louis, MO ) solution and counted using a light microscope. Images from each well were
analyzed using ImageJ software (National Institutes of Health, Bethesda, Maryland).
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ALDEFLUOR Staining and Flow Cytometry
The ALDEFLUOR kit (Stem Cell Technologies, Vancouver, BC) was used to
identify cells with high ALDH activity. Briefly, cells were suspended in assay buffer
containing a fluorescent ALDH substrate and incubated for 30 min at 37 °C. The ALDH
substrate passively diffuses into live cells and is then converted by ALDH into a
fluorescent product detectible by FL-1 (FITC) signal. A specific ALDH inhibitor,
diethylaminobenzaldehyde (DEAB) served as a negative control and allowed gating of
ALDH-positive cells. Becton, Dickinson, and Co. FACS Caliber (BD Biosciences San
Jose, CA) was used for all flow cytometry experiments.
Annexin V binding assays were conducted using FITC conjugated antibodies (BD
Bioscience) and propidium iodide to measure rates of apoptosis/cell death. Cells were
harvested and resuspended in 1x binding buffer (0.1 M HEPES, pH 7.4; 1.4 M NaCl; 25
mM CaCl2) at a concentration of 1x106 cells per mL. Staining was conducted following
manufacturer protocols. Briefly, 1x105 melanoma cells were incubated with 100 μM
lunasin for 24, 48, and 72 hours. Cells were suspended in 0.5 mL binding buffer and
stained with 5 μL PI, 5 μL Annexin antibody, or both for 15 minutes at room
temperature. Gates were set based on controls (unstained, PI only, Annexin only). 1x104
events were collected per run.
Cell cycle analysis was performed on synchronized melanoma cells; cells were
serum starved for 72 hours and then released by addition of FBS during lunasin or
vehicle treatment. 1x106 cells were harvested and resuspended in 200 μL PBS. Cells
were slowly added to 4 mL ice cold 70% ethanol for overnight fixation at -20˚C. After
fixation, cells were spun down at 300g for 10 minutes and resuspended in 0.5 mL of PI
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master mix (40 μg/mL PI, 100 μg/mL DNase in PBS) and incubated at 37˚C for 30
minutes prior to flow anaylsis.
Fluorescence-assisted Cell Sorting
A MoFlo cell sorter (Beckman Coulter, Brea, CA) was used for all
fluorescence assisted cell sorting (FACS). ALDH-positive and ALDH-negative fractions
were isolated using FL1 signal and collected for subsequent in vitro and in vivo
experiments. Sorted cells were confirmed to be positively stained for ALDH by
fluorescent microscopy under blue laser (illumination at 488 nm). Because a relatively
large population of melanoma cells expressed at least some basal level of ALDH, only
ALDH-positive cells with high FL1 intensity were collected. A representative histogram
for FACS based on the ALDH biomarker is shown in Figure 3.
Formation of Multicellular Oncospheres
Stem-like cells isolated by FACS were cultured in low adherent T-25 flasks
(Corning, Corning, NY) in DMEM culture media supplemented with 2% FBS at a
density of 1x104 cells/mL. Cultures were grown for 28 days and treated every 48 hours
during this time period with lunasin or vehicle in DMEM culture media. Oncospheres
began to form around 14 days and continued to grow until they were harvested,
dissociated, and counted. Visual counts of oncospheres were performed by light
microscopy and analyzed using ImageJ software.
In vivo Xenograft Model
In vivo experiments using 6-8 week old, male athymic nude mice (Jackson labs
Stock# 002019, Bar Harbor, Maine) illustrated the anticancer effects of lunasin in a
xenograft model. Briefly, mice were injected subcutaneously (s.c.) with 2.5x106 A375
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cells reconstituted in 100 μL phosphate buffered saline (PBS) on the right flank.
Intraperitoneal (IP) injections of 30 mg/kg lunasin reconstituted in 50 mM phosphate
buffer, pH 7.4 (PB) were administered starting immediately after s.c. injection of tumor
cells and repeated every 24 hours. Noticeable tumor formation was observed
approximately 14 days post-injection and measured every other day thereafter.
Experimental endpoint was set at tumor volumes exceeding 20 mm in diameter or
ulceration of tumor tissues. At endpoint, mice were sacrificed and organs were resected
for slide preparations.
For MMIC studies, 1x104 ALDH+ cells were reconstituted in Hank’s Balanced
Salt Solution (HBSS) +calcium +magnesium (Invitrogen) with an equal volume of
Matrigel (BD Biosciences) and injected on the dorsal side of the mice at a total volume of
100 μL. Palpable tumor formation was observed at approximately 16 days post-injection
and measured every other day as described above. Again, organs were resected and
blood was drawn via cardiac puncture upon sacrifice for future processing.
SDS-PAGE and Immunoblot
Cultured cells were harvested by using enzyme free dissociation buffer to
minimize protein degradation, spun down, and washed in ice-cold PBS. After pelleting,
cells were resuspended in appropriate amounts of RIPA buffer (250 mM Tris-HCl, pH
7.5, 5 mM EDTA, 750 mM NaCl, 0.5% Lauryl sulfate, 2.5% Deoxycholic acid, 5%
Igepal CA-630, Protease inhibitor cocktail containing 4-(2-aminoethyl) benzenesulfonyl
fluoride (AEBSF), pepstatin A, bestatin, leupeptin, aprotinin and trans-epoxysuccinyl-Lleucyl-amido(4-guanidino)-butane (E-64) (Sigma-Aldrich). Protein concentrations of cell
lysates were determined by a bicinchoninic acid (BCA) assay (Thermo Fisher Scientific,
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Waltham, MA). 20 μg of protein were loaded into 10% polyacrilamide gels (BioRad,
Hercules, CA) and run at 100 volts for 1 hour. The protein was then transferred to a
polyvinylidene difluoride (PVDF) membrane (BioRad) at 350 milliamps for 1 hour. The
PVDF membrane was blocked with 5% bovine serum albumin (BSA) or non-fat dry milk
for 1 hour. After several washing steps, primary antibodies were incubated with
membrane at 4˚C overnight. FAK (Cell Signaling, Danvers, Massachusetts), AKT (Cell
Signaling), phospho-FAK (Cell Signaling), and phospho-AKT (Cell Signaling)
monoclonal antibodies were diluted in Tris Buffered Saline with 0.1% Tween (TTBS) at
1:1000 – 1:2000 v/v. After three washes, secondary antibodies at 1:10,000 dilutions (Cell
Signaling) were incubated with the membrane for 1 hour at room temp.
Electrochemiluminescent (ECL) substrate/enhancer solutions (Thermo Fisher) were
allowed to activate horseradish peroxidase (HRP) signal on membrane for 2-3 minutes;
Chemiluminescence was developed on x-ray film and/or detected using a ChemiDoc
station (BioRad).
Non-steroidal anti-inflammatory drug (NSAID) Toxicological Panel and Complete Blood
Count (CBC)
Whole blood was drawn from athymic nude mice by cardiac puncture
immediately following CO2 asphyxiation and collected in serum separator tubes (BD
Biosciences) or EDTA coated collection tubes (BD Biosciences). 25 μL of whole blood
were collected in EDTA coated tubes and send to the RRC facility at the University of
Louisville for CBC analysis. After 1 hour post-collection, whole blood collected in
serum separator tubes were centrifuged for 10 minutes at 10,000 g. 250 μL of serum was
removed from each sample, collected in a 1.5 mL eppendorf tube, and send to the RRC
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facility for NSAID toxicological analysis. Liver damage was assessed by levels of
alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline
phosphatase (ALKP). Kidney damage was assessed by level of blood urea nitrogen
(BUN) and creatinine (CREA).
Statistical Analysis
All data were analyzed in three independent experiments. In vitro results were
analyzed using GraphPad Prism (v 5.0) software and shown as mean ± standard deviation
(SD). Comparison of results from treated versus control cells was done using unpaired
Student’s t test. A p-value of less than 0.05 was considered statistically significant. In
vivo experiments were statistically analyzed using GraphPad Prism ANOVA analysis tool
(p<0.05), and shown as mean ± standard error (SEM). Individual data points were
compared by unpaired Student’s t test (p<0.05) to determine significance. Interactions
between lunasin and vemurafenib were determined to be antagonistic (< 1), additive (1),
or synergistic (> 1) by calculating the Drewinko Index. All samples were normalized to
appropriate controls and applied to the formula DI =

in which SF1 is equal to

the surviving fraction of drug1, effect2 is equal to the surviving fraction of drug2, and
effect3 is equal to the surviving fraction of the combination of drug1 and drug2.
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RESULTS
Lunasin has modest antiproliferative effects on melanoma in adherent cell culture
Proliferation assays remain an effective and high throughput method for screening
drug efficacy. We used a tetrazolium based proliferation assay to determine if lunasin
displayed a significant antiproliferative effect on melanoma cell lines. MTS results
(Figure 4) indicate that lunasin marginally inhibits proliferation in adherent conditions
and has an additive interaction with the B-Raf inhibitor vemurafenib as calculated by
Drewinko Index assessment (DI = 1). We replicated these experiments with cells isolated
based on high expression of the ALDH biomarker using FACS. ALDH positive cells
showed no significant difference from the parental cell lines in terms of sensitivity to
lunasin using this culture method. Figure 4 illustrates that lunasin interacted additively
with vemurafenib in both parental and ALDH+ cells as assessed by DI.
Lunasin reduced anchorage-independent growth of melanoma cells in soft agar
Soft agar assays represent a robust system for screening cancer cells for drug
sensitivity that is thought to be more representative of potential in vivo effects. We
observed a heightened sensitivity of melanoma cells to lunasin when plated in soft agar
versus adherent culture conditions (Figure 5). This is consistent with previous studies in
our lab in which lunasin-insensitive NSCLC lines displayed lunasin sensitivity in a nonadherent format (McConnell and Davis, unpublished data). Lunasin showed a significant
antiproliferative effect on A375 melanoma cells plated in soft agar. 30 μM lunasin
reduced colony formation by approximately 25%, while 100 μM lunasin inhibited colony
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formation by 38% (Figure 5A). Along with decreased colony counts, a noticeable
reduction in the size and change in phenotype accompanies lunasin treatment (Figure 5D)
versus vehicle treated A375 cells (Figure 5E). Cells treated with lunasin formed colonies
that tended to be less dense and displayed a somewhat dissociated phenotype.
Furthermore, we found that lunasin interacts additively with the specific B-Raf inhibitor
vemurafenib. A combination of 100 μM lunasin plus 300, 700, and 1000 nM
vemurafenib yielded a significant decrease in colony formation, illustrating the potential
application of lunasin as an adjuvant therapy in melanoma patients.
Lunasin alone shows an antiproliferative effect on the SKMEL-28 melanoma cell
line (Figure 5B). Concentrations of 30 μM and 100 μM reduced colony formation of
SKMEL-28 melanoma cells by 14% and 20%, respectively (Figure 5B). The additive
effect of lunasin was again measured with vemurafenib co-treatment; however, a
statistically significant additive effect was not obtained at 700 nM vemurafenib.
Anchorage independent growth is a hallmark of cancer; these data illustrate the utility of
chemotherapeutics in disrupting proliferation of cancer cells in non-adherent conditions.
From this, we concluded that concurrent treatment of lunasin and the B-Raf inhibitor
vemurafenib could be a legitimate therapeutic strategy in malignant melanomas with the
V600E mutation.
Lunasin reduces the melanoma stem cell population in vitro
We conducted initial experiments in which A375 and SKMEL-28cells were
treated with 1 μM vemurafenib, 100 μM lunasin, and a combination of both agents.
Melanoma stem cell markers (e.g. ALDH) in the cell population were analyzed by flow
cytometry. ALDH staining has been recognized as a technique to distinguish and isolate
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melanoma stem cells from bulk tumor populations. Our results indicated that both
vemurafenib and lunasin are able to dramatically reduce the population of cells
expressing measureable levels of ALDH (Figure 6). This reduction in ALDH expression
is time dependent. An overall reduction in ALDH-positive cells was seen with lunasin
treatment, vemurafenib treatment, and in combination treatment groups.
Lunasin alone had a significant effect on ALDH expression in melanoma cells
versus vehicle treatment (Figure 8). ALDH positive populations were reduced by nearly
50% in lunasin treated SKMEL-28 cells at 24 hours (Figure 8B). This effect was seen at
later time points, albeit, it was not significantly different from controls. In A375 cells,
ALDH positive populations were reduced by lunasin treatments; ALDH expressing cell
populations were reduced 56%, 35%, 18%, and 22% for 24, 48, 72, and 96 hour time
points, respectively (Figure 8A). By effectively reducing the tumor initiating cells in
culture, lunasin may inhibit primary tumor formation or alter metastatic growth by
inducing terminal differentiation of cancer stem cells or by reducing CIC pools available
to invade distant tissues.
Cell cycling and apoptotic effects on melanoma
Trypan blue exclusion tests were performed in concurrence with annexin binding
assays to measure apoptotic rates within melanoma cell populations. Initial experiments
suggest that lunasin has little effect on cell viability; however, potentiates the apoptotic
effects of vemurafenib in combination treatments (Figure 10). At the later time points, it
was clear that a number of cells in both A375 and SKMEL-28 treated samples were dead
or dying; however, these observations were apparent in both control and lunasin treated
samples. Results from later annexin binding assays did not show a definitive increase in
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early or late apoptotic populations within either cell line at 24, 48, or 72 hours in response
to 100 μM lunasin (Figure 11). Apoptotic and necrotic profiles for each treatment and
time point were generated, but no significant difference was seen in either cell line;
although, a clear trend in increasing early and late apoptotic cells was observed with
lunasin treatment. We therefore concluded that lunasin does not induce apoptosis or
cause a necrotic response in the parental melanoma cell lines; however, we expect to
isolate CICs based on the ALDH biomarker and determine if lunasin induces a selective
apoptosis response in this subset of cells.
Cell cycle analysis was performed using propidium iodide (PI) staining of DNA
(Figure 9). Briefly, cells were permeablized and fixed in 70% ethanol over night and
resuspending in a PI master mix (PI 40 μg/mL, RNase 100 μg/mL in PBS). Flow
analysis commenced after a 30 minute incubation. Interestingly, lunasin had little effect
on cell cycling of either melanoma cell line before the 72 hour time point. However, at
72 hours, a decrease of cells in S-phase was seen. These data may suggest lunasin has a
delayed effect on cellular proliferation, and causes accumulation of cells in G0/G1 and
G2 phases of the cell cycle. Treatment with vemurafenib caused a decrease in S-phase
throughout the time course, and an accumulation of cells in G0/G1 can be seen in both
cell lines. Combination treatment curves were similar to treatment with the B-Raf
inhibitor, however, S-phase cycling was further reduced, and frequency of sub-G1/superG2 cells was modestly increased.
Lunasin reduced phosphorylation of Akt and Fak in melanoma cells
Since lunasin was effective at inhibiting the growth of melanoma cells as colonies
in soft agar, we studied whether it affects the signaling pathways associated with cell
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growth and survival. FAK and AKT are downstream mediators of integrin signaling.
Figure 12 illustrates that total FAK (125 kDa) remains unchanged with lunasin treatment;
however, tyrosine phosphorylation (Y397) is significantly impaired. We next examined
the serine phosphorylation (Ser473) of Akt (60 kDa), a downstream signal molecule of
FAK. As expected, the phosphorylation of Akt was observed in untreated cells and
inhibited by treatment with lunasin. These results confirm that downstream mediators of
integrin signaling are severely affected by lunasin. By effectively reducing active forms
of Akt and Fak, signal transduction is interrupted, which may stimulate antiproliferative
and antisurvival cell signaling. Inhibiting these pathways may sensitize CICs with
superior survival signaling and chemoresistance to traditional or targeted therapies (e.g.
vemurafenib).
In vitro effects of lunasin were potentiated in melanoma stem cells
In order to determine whether or not lunasin has a selective apoptotic or
antiproliferative effect on cancer stem cells, in vitro assays measuring proliferation and
anchorage-dependent growth were performed, and the results from the ALDH-positive
populations were compared to the parental lines. Overall, lunasin had an increased effect
in the ALDH+ sorted cells. 100 μM lunasin reduced colony forming ability in soft agar
by approximately 40% and 75% in A375 and SKMEL-28 cell lines, respectively (Figure
14A). Interestingly, a reduction in colony size accompanied lunasin treatment in both
cell lines versus vehicle treatment (Figure 14B-E)
CICs have been reported to have enhanced ability to form oncospheres in low
adherent conditions. We assessed the ability of lunasin to disrupt formation of
oncospheres derived from sorted samples based on the ALDH biomarker. 100 μM
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lunasin almost completely inhibited spheroid formation in the A375 cell line versus
control (Figure 13B and Figure 13C), while reducing spheroid counts and size in
SKMEL-28 cells (Figure 13A). When spheres were dissociated and counted, viability
did not significantly change due to lunasin treatment; however, slightly reduced cell
counts as determined by trypan blue exclusion assays were observed (data not shown).
Furthermore, lunasin inhibited foci formation when A375 CICs were dissociated and
replated at low density in adherent conditions (Figure 13D and Figure 13E). ALDH
positive cells quickly grew in tightly packed clusters of cells and formed foci within a
matter of days. Lunasin restores growth of these cells as a monolayer and inhibits foci
formation in adherent culture. These data suggest lunasin may convert the more
tumorigenic ALDH expressing cells to the less aggressive phenotype of a terminally
differentiated bulk tumor cell. More research into possible mechanisms for this effect is
warranted as little is known about the movement of melanoma cells in and out of the stem
cell compartment. Furthermore, a definitive link between cancer stem cells and integrin
signaling has yet to be established in the roles of CSC differentiation, metastasis, and
overall patient outcome.
Lunasin had significant antimelanoma effects in vivo:
Our results indicate lunasin substantially inhibits tumor formation and growth in
an athymic nude mouse xenograft model. 30 mg/kg injections of lunasin reduced tumor
volume by 35% and 55% with intravenous (Figure 15) and intraperitoneal (Figure 16)
injections, respectively. IV injections were administered every other day; IP every day.
Tumor mass was also significantly decreased by lunasin treatments. Upon necroscopy,
whole tumors were resected and a wet tumor weigh was measured. IP and IV lunasin
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treatments resulted in a 46% and 34% decrease in wet tumor weights upon endpoint of
the experiment. These data delineate lunasin’s bioavailability and anticancer effects in an
in vivo model.
Non-steroidal Anti-inflammatory Drug (NSAID) toxicological panels showed
lunasin treatments did not alter circulating plasma levels of liver enzymes ALKP, ALT,
or AST. These data suggest lunasin does not induce a toxicological response in mice and
is safe for future therapeutic applications. Furthermore, renal function was not impaired
as measured by BUN and CREA. Complete blood count (CBC) analysis revealed lunasin
does not significantly alter levels of leukocytes, erythrocytes, or thrombocytes compared
to control.
Lunasin selectively inhibits MSC proliferation in vivo
Male athymic nude mice (6-8 weeks old) were transplanted with 1x104 cells that
had previously been sorted using the ALDEFLUOR staining kit in an equal volume of
HBSS (with calcium and magnesium) and Matrigel. Tumor formation was established at
16 days after injection and measured every other day thereafter. Control vehicle and 30
mg/kg lunasin were injected IP every 24 hours for the duration of the experiment. Our
results demonstrate the selective effect of lunasin on melanoma stem cells expressing the
ALDH biomarker. These cells are generally accepted to have enhanced tumorigenic
capacity versus non-sorted bulk tumor cells. Compared to our previous study in which
we injected 2.5x 106 bulk A375 cells, MSCs displayed superior tumor forming ability.
MMICs established palpable tumors in a similar amount of time compared to
parental tumor cells, however, this experiment utilized Matrigel in order to keep MMICs
localized to subcutaneous tumor growth. Matrigel contains growth factors which may
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boost cell proliferation; therefore, we concede that our MMIC and parental models are
not comparable in terms of tumor growth rates. Lunasin did not decrease the number of
tumors formed, but reduced tumor burden by 74%, a nearly 50% increased effect versus
parental A375 cells. Onset of tumor formation was delayed in lunasin treated mice;
tumors also displayed linear growth versus the exponential growth seen in control mice.
Wet tumor weights for lunasin treated mice were reduced by 66%, thus illustrating the
potential for lunasin to specifically target and inhibit growth of tumors derived from
CICs.
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DISCUSSION
Lunasin has previously been shown to have chemotherapeutic effects in a number
of cancer models [3, 23, 25, 83-85]. To our knowledge, this is the first study identifying
the anticancer effects of lunasin in a melanoma model. Therapies for treating patients
with malignant melanoma remain largely ineffective, despite novel targeted therapies that
show clinical improvements over traditional alkylating agents. Here we show that
lunasin has potential clinical utility as both an adjuvant therapy as well as a standalone
chemotherapeutic against malignant metastatic melanoma. Our data suggest that lunasin
interacts with subsets of integrin subunits and interrupts internal signaling cascades
induced by integrin activity.
Although HAT inhibition is generally regarded as the prime mechanism for
lunasin’s chemotherapeutic and chemopreventive attributes, we suggest the interactions
between the RGD-peptide and integrin dimers found on the cell surface to be essential
mechanisms in the in vitro and in vivo effects found in this study. Utilizing proximity
ligation assays, we have shown that lunasin interacts with specific integrins (Ianaba and
Davis, unpublished data), evidence supported by recent studies on integrin mediated
endocytosis [27].
We do not postulate that the described effects are due to the epigenetic effects
stimulated by lunasin treatment; though, we have found that lunasin does indeed affect
patterns of histone acetylation in melanoma cells in vitro (data not shown). Because
integrins are explicitly involved in cell adhesion and division, we concluded that
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reductions in clonogenic capacity in soft agar and formation of multicellular oncospheres
in low adherent culture are attributed to the disruption of adhesive signaling mediated by
integrins. We agree that HAT inhibition does have global cellular effects; however, we
believe that lunasin binding of integrins through its RGD domain is responsible for
lunasin’s anticancer activity in our melanoma models. However, in vivo effects may
stem from a variety of cellular effects induced by lunasin including integrin antagonism,
epigenetic modifications, and immunomodulatory functions.
Integrin signaling can regulate the stem cell processes of self-renewal,
differentiation, and proliferation [86]. We have shown that lunasin treatment altered
these processes and diminished intracellular interactions with Akt and Fak in vitro and
resulted in decreased tumor burden in vivo. Though lunasin decreased tumor burden in
mice injected with parental A375 melanoma cells, these effects were exacerbated in
MMIC populations in our xenograft models. Furthermore, we confirmed that lunasin
depleted the stem cell pool by reducing ALDH signal in established melanoma cell lines.
These effects may be associated with the ability of lunasin to induce terminal
differentiation of CICs or by altering downstream mediators of integrin signaling. The
enhanced effects seen in MMIC populations suggests that cancer stem cells may rely on
integrin signaling for proliferation and differentiation, more so than bulk tumor
populations. These finding are consistent with recent studies that suggest FAK as well as
β1 integrin subunits regulate stem cell pools in breast cancer [87].
Fak normally functions as a scaffolding protein to mediate signal transduction,
however, Fak also serves as a non-receptor tyrosine kinase mediating signal transduction
from external stimuli. Several studies correlate Fak overexpression or amplification with
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advanced disease resulting in poor prognosis [88, 89], consequently, targeting of FAK
may provide a novel therapeutic strategy for inhibiting metastatic disease progression.
FAK has been shown to arbitrate stem cell maintenance and differentiation in cancer
models [50, 51]. FAK association and activation of PI3K leads to increased production
of phospholipids, which can in turn activate Akt kinase [90, 91]. Again, these finding are
consistent with the results in our melanoma model as lunasin decreased phosphorylation
of Akt. Therefore, integrin signaling through FAK may play an essential role in
melanomagenesis or disease progression and metastasis; a pathway targeted by the
lunasin peptide.
Crosstalk between PI3K/Akt and NOTCH signaling pathways in melanoma has
been well documented [92, 93]. NOTCH signaling has been implicated in stem cell
processes such as self-renewal, differentiation, survival, and proliferation [94, 95]. It is
plausible that the decreased Akt phosphorylation seen in melanoma cells is mediated
through NOTCH signaling. Further studies are necessary to clarify whether or not
lunasin induces changes in the PI3K/Akt pathway through NOTCH family receptors.
Another aspect of melanoma development is the theory of direct phenotype
switching [96, 97]. To summarize, three distinct compartments exist in cancers; a highly
proliferative cell with low invasive capability, a differentiated phenotype derived from
daughter cells of divided stem-like cells, and an invasive, stem-like, quiescent phenotype
that regenerates stem cell pools. Switching between these subsets may rely on certain
genes such as microphthalmia-associated transcription factor (Mitf) and NOTCH.
NOTCH activity is frequently elevated in melanomas; it also maintains melanoctye stem
cell populations [98]. As discussed previously, NOTCH can mediate PI3K/Akt
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signaling; overexpression of AKT by NOTCH1 provides a key step in promoting an
invasive phenotype [99]. It has been shown that NOTCH1 is able to hyperactivate
PI3K/Akt signaling through NF-ĸB [93], a pathway previously revealed to be inhibited in
human macrophages by lunasin treatment [2].
Mitf has been established as a differentiation marker in melanocytes; however,
Mitf has also been reported to mediate proliferation, differentiation, and plasticity of
melanoma cells [100]. Insightful studies have addressed that melanomas with a negative
Mitf phenotype are generally quiescent, yet highly invasive [101]. Inversely, melanoma
cells highly expressing MITF proliferate rapidly, but do not seem to metastasize. In
support of these findings, inhibition of MITF increased expression of stem cell markers
Nanog and Oct4 resulting in enhanced tumor growth in C57/B6 mice [102]. Again,
culture conditions played a major role in expression of differentiation and stem markers
[100, 103]. Hoek and Goding summarize: “If the combination favours the proliferative
phenotype over the invasive, a tumour may grow rapidly, but for a given size, it will seed
fewer metastases than a tumour whose cells are not subject to a proliferative phenotype
bias.” [97] This hypothesis highlights the potential of selectively targeting cancer stem
cells instead of relying on drugs targeting rapidly dividing cell populations to increase the
overall efficacy of treatment in metastatic melanomas.
Clearly, these signaling pathways are implicated in both physiological and cancer
stem cell processes. Our results show an apparent decline in cancer stem cell pools that
may be influenced by these pathways; however, the potentiated effect in ALDH positive
MSCs cannot be fully explained until further research elucidates lunasin’s effects on
certain genes and gene products responsible for maintenance, proliferation, and
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differentiation of stem-like cancer cells. Our data hints that lunasin may alter stem pool
maintenance and proliferation, and therefore, has clinical utility in cases of late stage
melanoma in which traditional therapies have failed. Future studies in our lab will focus
on exploring the alterations induced by lunasin on cancer stem cell populations in
established melanoma lines.

30

SUMMARY AND CONCLUSIONS
The soy-derived peptide lunasin has significant activity as a chemopreventive [7];
however, lunasin also serves as an anticancer agent in established cancer models [24, 83].
Lunasin treatment reduces the capacity of melanoma cells to form oncospheres in low
adherent culture as well as inhibits clonal growth in soft agar. We believe these results
stem from an interaction between lunasin and integrins on the ECM through its RGD
domain, and results in decreased phosphorylation of intracellular signaling proteins such
as Fak and Akt. In vivo studies show lunasin significantly decreased tumor growth in
athymic nude mice injected subcutaneously with A375 melanoma cells. Tumor volume
and weight were reduced by 55% and 46%, respectively. These data illustrate the
potential clinical utility of lunasin against malignant melanoma.
Furthermore, we present a unique study showing the enhanced effects of lunasin
against stem-like melanoma cells which display superior tumor forming capability
compared to bulk tumor cells. Using ALDH, a recognized MMIC biomarker [77], we
isolated cells expressing distinctively higher levels of the enzyme and subjected them to
further in vitro testing. We found that MMIC response to lunasin treatment was
potentiated versus the parental cell lines both in vitro and in vivo. 30 mg/kg lunasin
treatment reduced tumor burden in our melanoma xenograft model by approximately
75%. Despite using appreciably fewer cells to initiate tumor formation, ALDH
expressing cells formed palpable tumors within a comparable amount of time versus bulk
tumor populations.
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The functional assays in this study illustrate the prospective use of lunasin as a
chemotherapeutic against melanomas in which traditional therapy has failed.
Additionally, we showed that extended lunasin treatment displayed no toxicological
effects versus control in our animal model. However, we have only begun to elucidate
mechanisms in which lunasin acts as an anticancer agent. While epigenetic effects
undoubtedly play a major role in tumorigenesis, we feel that lunasin has several critical
effects on integrin signaling and further, CIC maintenance and proliferation resulting in
the augmented effects seen in MMICs.
It must be taken into consideration that several theories exist in which cells are
able to move between stem and differentiated cell compartments; theories in which
melanoma serves as a prime example. If this is the case, more research is warranted to
determine if A) lunasin is inducing terminal differentiation of melanoma cells, B)
confirm ALDH as a viable biomarkers for MMIC populations by utilizing alternative
markers, and C) analyze the alterations in gene expression patterns induced by lunasin
treatment to further advance our understanding of the peptides anticancer effects.
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Figure 1: Lunasin represses transcription of target genes by inhibiting HAT binding to histone
tails. It is proposed that lunasin binding causes hypoacetylation of chromatin leading to cell
cycle arrest and apoptosis
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Adapted from Kuphal
et al. Integrin
signaling in
malignant melanoma.
2005.

Figure 2: Integrin signaling mediated by FAK and ILK can lead to abundant cellular effects including
proliferation, cell survival, migration, and differentiation.
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DEAB
ALDH +

Figure 3: FACS based on the ALDH biomarker resulted in ~20% of the
A375 melanoma cell population staining positive. DEAB served as a
negative control by inhibiting ALDH cleavage of the fluorescent
substrate. Untreated cells were sorted based on our positive (untreated)
control.
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Figure 4: Tetrazolium-based proliferation assays (i.e. MTT) showed A375 and SKMEL-28
melanoma cell lines are relatively insensitive to lunasin (100 μM) treatment in adherent conditions.
ALDH-positive cells showed little sensitivity in this format as well, however, lunasin still interacted
additively with the B-Raf inhibitor vemurafenib as calculated by Drewinko Index (DI).
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Figure 5: Lunasin and vemurafenib combination treatments show the potential of lunasin as an
adjuvant treatment of (A) A375 and (B) SKMEL-28 melanoma cells by reducing colony forming
ability in soft agar. (C) 100 μM lunasin (bottom well) reduced colony formation by approximately
40% and 20% in A375 and SKMEL-28 melanoma cell, respectively. (D) Control A375 colonies
formed tight, well defined colonies in soft agar that were larger than (E) lunasin treated colonies.
Significance denoted by asterisk as assessed by unpaired Student’s T test (p < 0.05).
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Figure 6: Lunasin and vemurafenib treatment decreased the number of ALDHhigh cell populations in
A375 and SKMEL-28 melanoma cells. Combination treatment further reduced ALDH expression in
both cell lines, however, this effect was less pronounced at later time points. (n = 1)
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Figure 7: ALDH represents a unique biomarker to identify and isolate melanoma stem cells.
Here we use the specific ALDH inhibitor DEAB as a negative control (A) to determine
parameters for ALDH-positive (B) cells. We show that 100 μM lunasin (C) treatments for 24
hours reduced ALDH expressing populations in melanoma cell lines, while concurrently
decreasing mean fluorescent intensity (MFI) of ALDH-positive cells.
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Figure 8: ALDH expression was significantly reduced by 100 μM lunasin
treatments (A) lunasin reduced ALDH expressing cell populations by 56%, 35%,
18%, and 22% for 24, 48, 72, and 96 hour timepoints, respectively. (B) ALDH
expressing cell populations were significantly reduced at 24 hours in SKMEL28
melanoma cells, but only marginally at later time points. Statistical significance
was determined by Student’s T test with p values set at 0.05.
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Figure 9: Cell cycle analysis by PI stain. Lunasin had little effect on cell cycling at early time points,
but caused a significant drop in cells in S-phase after 72 hours for the A375 cell line. Vemurafenib
inhibited cell cycling throughout the experiment; this effect was enhanced with lunasin co-treatment.
(n=1)
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Figure 10: Annexin V binding assays were used to assess apoptotic profiles for A375 and SKMEL-28
melanoma cell lines in response to vemurafenib and lunasin treatments. Lunasin again potentiated the
effects of vemurafenib in both cell lines resulting in decreased viability and a concomitant increase in
late apoptotic cells.
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Figure 11: Apoptotic profiles were generated using the Annexin V binding assay. A375 cells treated
with 100 μM lunasin did not have a significant number of apoptotic cells versus vehicle treated cells
until 72 hours. Although significance was not evident, a trend of decreased viability due to lunasin
treatment was observed. Significance (p < 0.05) was determined by unpaired Student’s T test.
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Figure 12: Immunoblot analysis of 20ug total protein from A375
cell lysates. Lunasin treatment decreased phosphorylation of (B)
Fak and (D) Akt. Unphosphorylated protein content of (A) Fak and
(C) Akt remain stable in all samples. (E) Actin was used as a
reference protein to ensure equal protein was loaded in all lanes.
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Figure 13: 100 μM lunasin reduced formation of oncospheres in A375 and
SKMEL28 cell lines. (A) lunasin inhibited melanoma stem cells from forming
oncospheres in low adherent culture. (B) Control wells contained A375 spheroids
cultured for 28 days (C) lunasin treatment inhibited A375 oncosphere formation in
low adherent culture (D) A375 ALDH+ MSCs were replated into adherent T-25
flasks and allowed to form foci on the plate (E) lunasin treatment completely
inhibited foci formation. Significance is denoted by asterisk as assessed by Student’s
T test (p < 0.05).
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Figure 14: Colony formation in soft agar was significantly reduced with
100 μM lunasin treatment. (A) Colony formation in soft agar was
significantly reduced in both A375 and SKMEL-28 cell lines. Cell
proliferation was reduced as been by the smaller colony size in lunasin
treated A375 (B) and SKMEL-28 (D) cell lines versus phosphate buffer
controls (C,E). Significance is denoted by an asterisk and assessed by
Student’s T test (p < 0.05).
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Figure 15: A375 cells formed subcutaneous tumors in nude mice. IV injection of
30 mg/kg lunasin in athymic nude mice resulted in a 34% decrease in tumor
volume (A) and 35% decrease in tumor weight versus (B) phosphate buffer treated
control mice. Statistical significance was determined by ANOVA (p < 0.05) using
GraphPad software analysis.
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Figure 16: In-vivo xenograft models utilizing athymic nude mice illustrate the potential
therapeutic advantage to the soy-derived peptide lunasin. (A) Wet tumor weight from resect
tumor tissues. 30 mg/kg lunasin treatment reduced tumor weights by 46%. (B) Tumor volume
was reduced by 55% and represented a significant difference from phosphate buffer control as
determined by one-way ANOVA (p < 0.05)
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Figure 17: Lunasin showed no apparent liver (A) or kidney (B) damage as assessed by NSAID
toxicological panels. Complete blood counts (C,D,E) also illustrate the safety of continual
lunasin treatment. No significance was determined by Student’s T test (p < 0.05) between
treatment groups.
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Figure 18: Melanoma stem cell xenograft model (A) 30 mg/kg lunasin treatment reduced tumor
weight by 64% compared to phosphate buffer control. (B) Tumor volume was also significantly
reduced 74% versus control vehicle. Statistical significance was determined by ANOVA (p <
0.05) using GraphPad software analysis.

50

REFERENCES
1.

2.

3.
4.

5.

6.
7.

8.
9.

10.
11.
12.

13.
14.

15.
16.
17.

Garcia-Nebot, M.J., I. Recio, and B. Hernandez-Ledesma, Antioxidant activity and
protective effects of peptide lunasin against oxidative stress in intestinal Caco-2 cells.
Food and chemical toxicology : an international journal published for the British
Industrial Biological Research Association, 2014. 65: p. 155-61.
Cam, A. and E.G. de Mejia, RGD-peptide lunasin inhibits Akt-mediated NF-kappaB
activation in human macrophages through interaction with the alphaVbeta3 integrin.
Molecular nutrition & food research, 2012. 56(10): p. 1569-81.
Chang, H.C., et al., Soypeptide lunasin in cytokine immunotherapy for lymphoma. Cancer
immunology, immunotherapy : CII, 2014. 63(3): p. 283-95.
Hernandez-Ledesma, B., C.C. Hsieh, and B.O. de Lumen, Antioxidant and antiinflammatory properties of cancer preventive peptide lunasin in RAW 264.7
macrophages. Biochemical and biophysical research communications, 2009. 390(3): p.
803-8.
Odani, S., T. Koide, and T. Ono, Amino acid sequence of a soybean (Glycine max) seed
polypeptide having a poly(L-aspartic acid) structure. The Journal of biological chemistry,
1987. 262(22): p. 10502-5.
Seber, L.E., et al., Scalable purification and characterization of the anticancer lunasin
peptide from soybean. PloS one, 2012. 7(4): p. e35409.
Galvez, A.F., et al., Chemopreventive property of a soybean peptide (lunasin) that binds
to deacetylated histones and inhibits acetylation. Cancer research, 2001. 61(20): p.
7473-8.
Galvez, A.F. and B.O. de Lumen, A soybean cDNA encoding a chromatin-binding peptide
inhibits mitosis of mammalian cells. Nature biotechnology, 1999. 17(5): p. 495-500.
Jeong, H.J., Y. Lam, and B.O. de Lumen, Barley lunasin suppresses ras-induced colony
formation and inhibits core histone acetylation in mammalian cells. Journal of
agricultural and food chemistry, 2002. 50(21): p. 5903-8.
de Lumen, B.O., Lunasin: a cancer-preventive soy peptide. Nutrition reviews, 2005.
63(1): p. 16-21.
Jeong, H.J., et al., The cancer preventive peptide lunasin from wheat inhibits core histone
acetylation. Cancer letters, 2007. 255(1): p. 42-8.
Jeong, J.B., et al., Cancer-preventive peptide lunasin from Solanum nigrum L. inhibits
acetylation of core histones H3 and H4 and phosphorylation of retinoblastoma protein
(Rb). Journal of agricultural and food chemistry, 2007. 55(26): p. 10707-13.
Omoni, A.O. and R.E. Aluko, Soybean foods and their benefits: potential mechanisms of
action. Nutrition reviews, 2005. 63(8): p. 272-83.
Lee, M.M., et al., Soy and isoflavone consumption in relation to prostate cancer risk in
China. Cancer epidemiology, biomarkers & prevention : a publication of the American
Association for Cancer Research, cosponsored by the American Society of Preventive
Oncology, 2003. 12(7): p. 665-8.
Messina, M.J., et al., Soy intake and cancer risk: a review of the in vitro and in vivo data.
Nutrition and cancer, 1994. 21(2): p. 113-31.
Hernandez-Ledesma, B., C.C. Hsieh, and B.O. de Lumen, Lunasin, a novel seed peptide
for cancer prevention. Peptides, 2009. 30(2): p. 426-30.
Lam, Y., A. Galvez, and B.O. de Lumen, Lunasin suppresses E1A-mediated transformation
of mammalian cells but does not inhibit growth of immortalized and established cancer
cell lines. Nutrition and cancer, 2003. 47(1): p. 88-94.
51

18.

19.

20.

21.
22.

23.

24.

25.

26.

27.

28.
29.

30.
31.
32.

33.
34.
35.

Hsieh, C.C., B. Hernandez-Ledesma, and B.O. de Lumen, Lunasin-aspirin combination
against NIH/3T3 cells transformation induced by chemical carcinogens. Plant foods for
human nutrition, 2011. 66(2): p. 107-13.
Avvakumov, N., et al., Conserved molecular interactions within the HBO1
acetyltransferase complexes regulate cell proliferation. Molecular and cellular biology,
2012. 32(3): p. 689-703.
Santer, F.R., et al., Inhibition of the acetyltransferases p300 and CBP reveals a targetable
function for p300 in the survival and invasion pathways of prostate cancer cell lines.
Molecular cancer therapeutics, 2011. 10(9): p. 1644-55.
Ait-Si-Ali, S., et al., CBP/p300 histone acetyl-transferase activity is important for the G1/S
transition. Oncogene, 2000. 19(20): p. 2430-7.
Hernandez-Ledesma, B., C.C. Hsieh, and B.O. de Lumen, Relationship between lunasin's
sequence and its inhibitory activity of histones H3 and H4 acetylation. Molecular
nutrition & food research, 2011. 55(7): p. 989-98.
Hsieh, C.C., B. Hernandez-Ledesma, and B.O. de Lumen, Lunasin, a novel seed peptide,
sensitizes human breast cancer MDA-MB-231 cells to aspirin-arrested cell cycle and
induced apoptosis. Chemico-biological interactions, 2010. 186(2): p. 127-34.
Dia, V.P. and E. Gonzalez de Mejia, Lunasin induces apoptosis and modifies the
expression of genes associated with extracellular matrix and cell adhesion in human
metastatic colon cancer cells. Molecular nutrition & food research, 2011. 55(4): p. 62334.
Dia, V.P. and E. Gonzalez de Mejia, Lunasin potentiates the effect of oxaliplatin
preventing outgrowth of colon cancer metastasis, binds to alpha5beta1 integrin and
suppresses FAK/ERK/NF-kappaB signaling. Cancer letters, 2011. 313(2): p. 167-80.
Dia, V.P., et al., Structural property of soybean lunasin and development of a method to
quantify lunasin in plasma using an optimized immunoassay protocol. Food chemistry,
2013. 138(1): p. 334-41.
Cam, A., M. Sivaguru, and E. Gonzalez de Mejia, Endocytic mechanism of internalization
of dietary peptide lunasin into macrophages in inflammatory condition associated with
cardiovascular disease. PloS one, 2013. 8(9): p. e72115.
Playford, M.P. and M.D. Schaller, The interplay between Src and integrins in normal and
tumor biology. Oncogene, 2004. 23(48): p. 7928-46.
Moro, L., et al., Integrin-induced epidermal growth factor (EGF) receptor activation
requires c-Src and p130Cas and leads to phosphorylation of specific EGF receptor
tyrosines. The Journal of biological chemistry, 2002. 277(11): p. 9405-14.
Pu, C.Y., et al., RGD-modified endostatin fragments showed an antitumor effect through
antiangiogenesis. Anti-cancer drugs, 2012. 23(8): p. 788-802.
Smolarczyk, R., et al., Antitumor effect of RGD-4C-GG-D(KLAKLAK)2 peptide in mouse
B16(F10) melanoma model. Acta biochimica Polonica, 2006. 53(4): p. 801-5.
Buerkle, M.A., et al., Inhibition of the alpha-nu integrins with a cyclic RGD peptide
impairs angiogenesis, growth and metastasis of solid tumours in vivo. British journal of
cancer, 2002. 86(5): p. 788-95.
Geiger, B., et al., A chimeric N-cadherin/beta 1-integrin receptor which localizes to both
cell-cell and cell-matrix adhesions. Journal of cell science, 1992. 103 ( Pt 4): p. 943-51.
Howe, A., et al., Integrin signaling and cell growth control. Current opinion in cell
biology, 1998. 10(2): p. 220-31.
Persad, S., et al., Inhibition of integrin-linked kinase (ILK) suppresses activation of protein
kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer
52

36.

37.
38.
39.
40.
41.
42.
43.
44.
45.

46.
47.
48.
49.

50.

51.
52.
53.
54.

cells. Proceedings of the National Academy of Sciences of the United States of America,
2000. 97(7): p. 3207-12.
Berthet, V., et al., Role of endoproteolytic processing in the adhesive and signaling
functions of alphavbeta5 integrin. The Journal of biological chemistry, 2000. 275(43): p.
33308-13.
Fu, G., W. Wang, and B.H. Luo, Overview: structural biology of integrins. Methods in
molecular biology, 2012. 757: p. 81-99.
Hynes, R.O., Integrins: bidirectional, allosteric signaling machines. Cell, 2002. 110(6): p.
673-87.
Berrier, A.L. and K.M. Yamada, Cell-matrix adhesion. Journal of cellular physiology, 2007.
213(3): p. 565-73.
Pisano, M., et al., In vitro activity of the alphavbeta3 integrin antagonist RGDechi-hCit on
malignant melanoma cells. Anticancer research, 2013. 33(3): p. 871-9.
McGary, E.C., D.C. Lev, and M. Bar-Eli, Cellular adhesion pathways and metastatic
potential of human melanoma. Cancer biology & therapy, 2002. 1(5): p. 459-65.
Hood, J.D. and D.A. Cheresh, Role of integrins in cell invasion and migration. Nature
reviews. Cancer, 2002. 2(2): p. 91-100.
Hood, J.D., et al., Differential alphav integrin-mediated Ras-ERK signaling during two
pathways of angiogenesis. The Journal of cell biology, 2003. 162(5): p. 933-43.
Alavi, A., et al., Role of Raf in vascular protection from distinct apoptotic stimuli. Science,
2003. 301(5629): p. 94-6.
Matter, M.L. and E. Ruoslahti, A signaling pathway from the alpha5beta1 and
alpha(v)beta3 integrins that elevates bcl-2 transcription. The Journal of biological
chemistry, 2001. 276(30): p. 27757-63.
Aoudjit, F. and K. Vuori, Integrin signaling inhibits paclitaxel-induced apoptosis in breast
cancer cells. Oncogene, 2001. 20(36): p. 4995-5004.
Scatena, M., et al., NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell
survival. The Journal of cell biology, 1998. 141(4): p. 1083-93.
Kuphal, S., R. Bauer, and A.K. Bosserhoff, Integrin signaling in malignant melanoma.
Cancer metastasis reviews, 2005. 24(2): p. 195-222.
Lee, N., S.R. Barthel, and T. Schatton, Melanoma stem cells and metastasis: mimicking
hematopoietic cell trafficking? Laboratory investigation; a journal of technical methods
and pathology, 2014. 94(1): p. 13-30.
Danen, E.H., et al., Integrin beta 3 cDNA transfection into a highly metastatic alpha v
beta 3-negative human melanoma cell line inhibits invasion and experimental
metastasis. Biochemical and biophysical research communications, 1996. 226(1): p. 7581.
Desgrosellier, J.S. and D.A. Cheresh, Integrins in cancer: biological implications and
therapeutic opportunities. Nature reviews. Cancer, 2010. 10(1): p. 9-22.
Schatton, T. and M.H. Frank, Antitumor immunity and cancer stem cells. Annals of the
New York Academy of Sciences, 2009. 1176: p. 154-69.
Schatton, T., et al., Identification of cells initiating human melanomas. Nature, 2008.
451(7176): p. 345-9.
Reardon, D.A., et al., Cilengitide: an RGD pentapeptide alphanubeta3 and alphanubeta5
integrin inhibitor in development for glioblastoma and other malignancies. Future
oncology, 2011. 7(3): p. 339-54.

53

55.

56.

57.

58.

59.
60.
61.

62.
63.
64.
65.
66.

67.
68.
69.

70.
71.
72.
73.

(ACS), A.C.S. Skin Cancer Facts. [Online] 2014 3/14/2014 [cited 2014 April 24]; Available
from:
http://www.cancer.org/cancer/cancercauses/sunanduvexposure/skin-cancerfacts.
Howlader N, N.A., Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J,
Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA. SEER Cancer Statistics
Review, 1975-2011. 2014 [cited 2014 April 25]; based on November 2013 SEER data
submission, posted to the SEER web site, April 2014.]. Available from:
http://seer.cancer.gov/csr/1975_2011/.
Ji, Z., et al., Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses
melanoma viability and tumor growth. Clinical cancer research : an official journal of the
American Association for Cancer Research, 2013. 19(16): p. 4383-91.
Trunzer, K., et al., Pharmacodynamic effects and mechanisms of resistance to
vemurafenib in patients with metastatic melanoma. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology, 2013. 31(14): p. 1767-74.
Davies, H., et al., Mutations of the BRAF gene in human cancer. Nature, 2002.
417(6892): p. 949-54.
Chapman, P.B., et al., Improved survival with vemurafenib in melanoma with BRAF
V600E mutation. The New England journal of medicine, 2011. 364(26): p. 2507-16.
Rizos, H., et al., BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma:
Spectrum and Clinical Impact. Clinical cancer research : an official journal of the
American Association for Cancer Research, 2014. 20(7): p. 1965-77.
Sun, C., et al., Reversible and adaptive resistance to BRAF(V600E) inhibition in
melanoma. Nature, 2014. 508(7494): p. 118-22.
Nazarian, R., et al., Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or
N-RAS upregulation. Nature, 2010. 468(7326): p. 973-7.
Tuma, R.S., Getting around PLX4032: studies turn up unusual mechanisms of resistance
to melanoma drug. Journal of the National Cancer Institute, 2011. 103(3): p. 170-1, 177.
Reya, T., et al., Stem cells, cancer, and cancer stem cells. Nature, 2001. 414(6859): p.
105-11.
Clarke, M.F., et al., Cancer stem cells--perspectives on current status and future
directions: AACR Workshop on cancer stem cells. Cancer research, 2006. 66(19): p. 933944.
Clarke, M.F. and M. Fuller, Stem cells and cancer: two faces of eve. Cell, 2006. 124(6): p.
1111-5.
Krivtsov, A.V., et al., Transformation from committed progenitor to leukaemia stem cell
initiated by MLL-AF9. Nature, 2006. 442(7104): p. 818-22.
Sun, B., et al., The minimal set of genetic alterations required for conversion of primary
human fibroblasts to cancer cells in the subrenal capsule assay. Neoplasia, 2005. 7(6): p.
585-93.
Fang, D., et al., A tumorigenic subpopulation with stem cell properties in melanomas.
Cancer research, 2005. 65(20): p. 9328-37.
Monzani, E., et al., Melanoma contains CD133 and ABCG2 positive cells with enhanced
tumourigenic potential. European journal of cancer, 2007. 43(5): p. 935-46.
Boiko, A.D., et al., Human melanoma-initiating cells express neural crest nerve growth
factor receptor CD271. Nature, 2010. 466(7302): p. 133-7.
Chaffer, C.L., et al., Normal and neoplastic nonstem cells can spontaneously convert to a
stem-like state. Proceedings of the National Academy of Sciences of the United States of
America, 2011. 108(19): p. 7950-5.
54

74.
75.

76.
77.
78.

79.
80.

81.

82.
83.

84.

85.
86.

87.
88.
89.
90.
91.
92.
93.

Quintana, E., et al., Efficient tumour formation by single human melanoma cells. Nature,
2008. 456(7222): p. 593-8.
Girouard, S.D. and G.F. Murphy, Melanoma stem cells: not rare, but well done.
Laboratory investigation; a journal of technical methods and pathology, 2011. 91(5): p.
647-64.
Frank, N.Y., et al., VEGFR-1 expressed by malignant melanoma-initiating cells is required
for tumor growth. Cancer research, 2011. 71(4): p. 1474-85.
Boonyaratanakornkit, J.B., et al., Selection of tumorigenic melanoma cells using ALDH.
The Journal of investigative dermatology, 2010. 130(12): p. 2799-808.
Prasmickaite, L., et al., Aldehyde dehydrogenase (ALDH) activity does not select for cells
with enhanced aggressive properties in malignant melanoma. PloS one, 2010. 5(5): p.
e10731.
Luo, Y., et al., ALDH1A isozymes are markers of human melanoma stem cells and
potential therapeutic targets. Stem cells, 2012. 30(10): p. 2100-13.
Visus, C., et al., Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1specific CD8(+) T cells. Clinical cancer research : an official journal of the American
Association for Cancer Research, 2011. 17(19): p. 6174-84.
Carpentino, J.E., et al., Aldehyde dehydrogenase-expressing colon stem cells contribute
to tumorigenesis in the transition from colitis to cancer. Cancer research, 2009. 69(20):
p. 8208-15.
Ginestier, C., et al., ALDH1 is a marker of normal and malignant human mammary stem
cells and a predictor of poor clinical outcome. Cell stem cell, 2007. 1(5): p. 555-67.
Dia, V.P. and E.G. Mejia, Lunasin promotes apoptosis in human colon cancer cells by
mitochondrial pathway activation and induction of nuclear clusterin expression. Cancer
letters, 2010. 295(1): p. 44-53.
Pabona, J.M., et al., The soybean peptide lunasin promotes apoptosis of mammary
epithelial cells via induction of tumor suppressor PTEN: similarities and distinct actions
from soy isoflavone genistein. Genes & nutrition, 2013. 8(1): p. 79-90.
Kapoor, S., Lunasin: attenuating effects on tumour growth in systemic malignancies.
Food chemistry, 2014. 150: p. 174.
Nagy, T., et al., Mammary epithelial-specific deletion of the focal adhesion kinase gene
leads to severe lobulo-alveolar hypoplasia and secretory immaturity of the murine
mammary gland. The Journal of biological chemistry, 2007. 282(43): p. 31766-76.
Taddei, I., et al., Beta1 integrin deletion from the basal compartment of the mammary
epithelium affects stem cells. Nature cell biology, 2008. 10(6): p. 716-22.
Golubovskaya, V.M., F.A. Kweh, and W.G. Cance, Focal adhesion kinase and cancer.
Histology and histopathology, 2009. 24(4): p. 503-10.
Luo, M. and J.L. Guan, Focal adhesion kinase: a prominent determinant in breast cancer
initiation, progression and metastasis. Cancer letters, 2010. 289(2): p. 127-39.
Hennessy, B.T., et al., Exploiting the PI3K/AKT pathway for cancer drug discovery. Nature
reviews. Drug discovery, 2005. 4(12): p. 988-1004.
Guan, J.L., Integrin signaling through FAK in the regulation of mammary stem cells and
breast cancer. IUBMB life, 2010. 62(4): p. 268-76.
Hu, Y. and L. Fu, Targeting cancer stem cells: a new therapy to cure cancer patients.
American journal of cancer research, 2012. 2(3): p. 340-56.
Bedogni, B., et al., Notch1 is an effector of Akt and hypoxia in melanoma development.
The Journal of clinical investigation, 2008. 118(11): p. 3660-70.

55

94.
95.
96.

97.
98.

99.
100.
101.
102.
103.

Koch, U. and F. Radtke, Notch and cancer: a double-edged sword. Cellular and molecular
life sciences : CMLS, 2007. 64(21): p. 2746-62.
Muller, C.S., Notch signaling and malignant melanoma. Advances in experimental
medicine and biology, 2012. 727: p. 258-64.
O'Connell, M.P. and A.T. Weeraratna, Change is in the air: the hypoxic induction of
phenotype switching in melanoma. The Journal of investigative dermatology, 2013.
133(10): p. 2316-7.
Hoek, K.S. and C.R. Goding, Cancer stem cells versus phenotype-switching in melanoma.
Pigment cell & melanoma research, 2010. 23(6): p. 746-59.
Pinnix, C.C. and M. Herlyn, The many faces of Notch signaling in skin-derived cells.
Pigment cell research / sponsored by the European Society for Pigment Cell Research
and the International Pigment Cell Society, 2007. 20(6): p. 458-65.
Govindarajan, B., et al., Overexpression of Akt converts radial growth melanoma to
vertical growth melanoma. The Journal of clinical investigation, 2007. 117(3): p. 719-29.
Carreira, S., et al., Mitf regulation of Dia1 controls melanoma proliferation and
invasiveness. Genes & development, 2006. 20(24): p. 3426-39.
Cheli, Y., et al., Hypoxia and MITF control metastatic behaviour in mouse and human
melanoma cells. Oncogene, 2012. 31(19): p. 2461-70.
Cheli, Y., et al., Mitf is the key molecular switch between mouse or human melanoma
initiating cells and their differentiated progeny. Oncogene, 2011. 30(20): p. 2307-18.
Thurber, A.E., et al., Inverse expression states of the BRN2 and MITF transcription factors
in melanoma spheres and tumour xenografts regulate the NOTCH pathway. Oncogene,
2011. 30(27): p. 3036-48.

56

CURRICULUM VITAE
Christopher P. Shidal
151 Vernon Ave #2
Louisville, KY 40206
(270) 519-2207
Cpshid01@louisville.edu
Personal Statement:
My goals as a research fellow are to define the molecular interactions between
specific carcinogens and to characterize the roles of these interactions in the initiation of
cancer development. Furthermore, I expect to profile and advance the soy-derived
peptide lunasin as a direct chemotherapeutic in melanoma and lung cancers. Previous
academic history as well as direct work experiences has provided the basic knowledge
and confidence necessary to succeed on these projects. Background experience in the
field of pharmacology has allowed me to develop concepts and critical thinking skills
necessary to excel throughout my career. While I was an undergraduate at UK, I tested
domestic well water samples for coliform and coliphage, which established good
laboratory practices and techniques. My time as a quality assurance technician allowed
me to demonstrate my ability to work in a group. Furthermore, I was given the
opportunity to advance a number of projects independently and in a timely manner.
Although it was more geared toward production, my work in quality assurance permitted
me to learn a number of wet chemistry protocols and utilize various analytical
instruments (i.e. HPLC). This project will sharpen these skills and hopefully become a
solid base for future work in the field of pharmacology and toxicology.
Education:
INSTITUTION AND LOCATION
Paducah Community College
(Paducah, KY)
University of Kentucky
(Lexington, KY)
University of Louisville
(Louisville, KY) (expected)

DEGREE
(if
applicable)

DATES
ATTENDED

N/A

08/04 – 08/05

Biology

B.S.

08/05 – 08/08

Biology

M.S.

08-11 - Present

Toxicology

57

FIELD OF
STUDY

Positions and Honors:
Employment
 2003 - 2006
 2008
KY)
 2008 - 2010
KY)
 2011 - present
(Louisville, KY)
 2014 – present

Pharmacy Technician, Lourdes Hospital, (Paducah, KY)
Research Technician, University of Kentucky (Lexington,
Quality Assurance Technician, Air Products (Calvert City,
Predoctoral Researcher, University of Louisville
Visiting Research Associate, Indiana University

Volunteerism and Memberships





2001 - present
2004
2008 - 2011
2011 - present

Volunteer, Relay for Life (Sponsored by ACS)
Volunteer, Habitat for Humanity
Volunteer, ASPCA
Member, Society of Toxicology (SOT)

Honors
 2004 – 2005
 2004 – 2005
 2009-2010
(Company Award)
 2011-2013

Academic Scholarship, Paducah Community College
Deans List, Paducah Community College
Governor’s Safety and Health Award, Air Products
Graduate Fellowship, University of Louisville (IPIBS)

Publications:
Submitted Abstracts
Arrowood, Karen, et al. (2008) Characterizing the health risks associated with domestic
well water use in rural Western Kentucky leading to an intervention study. University of
Kentucky.
Shidal, Chris and Keith R. Davis (2012). Lunasin inhibits proliferation of non-small cell
lung cancer (NSCLC) in vitro. Research Louisville, University of Louisville.
Shidal, Chris and Keith R. Davis (2012). Lunasin inhibits proliferation of non-small cell
lung cancer (NSCLC) in vitro. J.G. Brown Cancer Center Retreat, University of
Louisville.
Shidal, Chris and Keith R. Davis (2013). Molecular intereactions between cadmium and
nitrosamine ketone potentiate carcinogenic potential of cigarette smoke. OVSOT 2013
Spring Meeting, University of Louisville.

58

Shidal, Chris and Keith R. Davis (2013). Profiling lunasin as an adjuvant treatment in
malignant melanoma. J.G. Brown Cancer Center Retreat, University of Louisville
Presentations
Shidal, Chris (2011). The soy peptide lunasin has antiproliferative effects on non-small
cell lung cancer. Departmental seminar, University of Louisville Pharmacology and
Toxicology Department.
Shidal, Chris (2012). Lunasin inhibits proliferation of non-small cell lung cancer
(NSCLC) in vitro. Research Louisville, University of Louisville.
Shidal, Chris (2012). Lunasin inhibits proliferation of non-small cell lung cancer
(NSCLC) in vitro. J.G. Brown Cancer Retreat, University of Louisville.
Shidal, Chris and Keith R. Davis (2013). Molecular intereactions between cadmium and
nitrosamine ketone potentiate carcinogenic potential of cigarette smoke. OVSOT 2013
Spring Meeting, University of Louisville.
Shidal, Chris and Keith R. Davis (2013). Profiling lunasin as an adjuvant treatment in
malignant melanoma. J.G. Brown Cancer Center Retreat, University of Louisville
Skills:

Cell Culture Work (monolayer and 3D cell cultures, along with cocultures), Assays for Cancer Cell Growth (Soft Agar, Proliferation,
Oncosphere Formation), General Lab Protocols (Slide Preparation
of Cultured Cells/Tissues, Confocal/Fluorescent Microscopy,
Immunoblot, Transient Tranfection of Plasmids, Functional knockdown using siRNA, Flow Cytometry/FACS, GC, Microarray),
Animal Work (IV/IP Injections in Mice, Resection of
Organ/Tumor Tissues), Statistical Analysis (GraphPad Prism,
CalcuSyn, MS Databases)
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